Coronavirus Disease 2019 (COVID-19) Vaccination in Cancer Patients

Study summary

The current study primarily aims to determine the status of vaccination in enrolled cancer patients and identify barriers to coronavirus disease 2019 (COVID-19) vaccination in cancer patients who have not been vaccinated. Secondary objectives include determining the rate of vaccination in those who have ever been COVID-19 positive and those who have never been COVID-19 positive. The study team also seeks to determine factors associated with vaccine-acceptance and vaccine-hesitancy in the adult cancer population, identify side effects of COVID-19 vaccines in vaccinated cancer patients and to examine the effect of COVID-19 vaccination on overall clinical outcome in cancer patients. The study team will be conducting telephone interviews/surveys with up to130 adult cancer patients for data collection.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedCOVID-19 vaccine hesitancy and acceptance survey

The study team can explain what participation involves.

Who it may be forMalignancies Multiple

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 9, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Monika Joshi

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Monika Joshi
Interventions being studied: Other: COVID-19 vaccine hesitancy and acceptance survey

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Current or past medical history of invasive malignancy (any type) that has been treated at PSCI 2. Patients who are at least 18-years-old and younger than 90-years-old 3. Patients need to have working telephone /ability to converse. Interpreter could be used to get help with survey if not English speaking. 4. Patients who have had previous COVID-19 infection are also eligible.

Reasons someone may not be able to joinExclusion criteria

1. Patients who have not been treated or have been seen for current or past medical history of invasive malignancy (any type) at Penn State Cancer Institute 2. Patients who are under the age of 18 and older than 89-years-old 3. Patients who cannot provide consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Penn State Cancer InstituteHershey, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 9, 2024. Always confirm current availability with the study team.

View original record ↗